(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 8.95% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Ironwood Pharmaceuticals's revenue in 2026 is $389,316,000.On average, 6 Wall Street analysts forecast IRWD's revenue for 2026 to be $77,550,411,926, with the lowest IRWD revenue forecast at $73,189,729,725, and the highest IRWD revenue forecast at $80,870,082,461. On average, 6 Wall Street analysts forecast IRWD's revenue for 2027 to be $80,635,441,737, with the lowest IRWD revenue forecast at $75,623,714,144, and the highest IRWD revenue forecast at $84,825,926,792.
In 2028, IRWD is forecast to generate $83,076,035,754 in revenue, with the lowest revenue forecast at $76,757,260,180 and the highest revenue forecast at $88,798,295,118.